EOLS
EOLS clinical trials: Evolus, Inc.
Every trial on ClinicalTrials.gov where Evolus, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 6
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
EOLS on the catalyst calendar · EOLS registry changes
- Primary completion Apr 13, 2026ActualNo phase registeredNCT05481931Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar LinesEvolus, Inc. · Glabellar Frown LinesCompletedEOLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2023ActualPhase 2NCT05320393Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesEvolus, Inc. · Glabellar Frown LinesCompletedEOLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2016ActualPhase 2NCT02428608Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006Evolus, Inc. · Glabellar Frown LinesCompletedEOLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT02184988Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar LinesEvolus, Inc. · Glabellar Frown LinesCompletedEOLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2015ActualPhase 3NCT02334436A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002Evolus, Inc. · Glabellar Frown LinesCompletedEOLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 3NCT02334423A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001Evolus, Inc. · Glabellar Frown LinesCompletedEOLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 4NCT06903975BoTox Into the Sternocleidomastoid Muscles (SCM)Boston Medical Center · Neck Muscle IssueRecruitingEOLSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2025ActualPhase 1NCT06604832Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and TextureKalpna Kay Durairaj, MD, FACS · Skin AgingCompletedEOLSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2024ActualEarly Phase 1NCT05807412Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead RhytidesLupo Center for Aesthetic and General Dermatology · RhytidesCompletedEOLSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2023ActualEarly Phase 1NCT05129319Jeuveau Treatment of Glabellar Lines Using OLD Versus COLDClinical Testing of Beverly Hills · Glabellar Frown LinesCompletedEOLSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner